Amoéba: US commercial launch in preparation

(CercleFinance.com) - French 'greentech' Amoéba announced on Thursday that it was beginning to prepare the commercial launch of its plant protection products in the USA, with a view to registration expected during 2025.


This announcement comes as the US Environmental Protection Agency (EPA) has confirmed the admissibility and completeness of the registration dossier for its two biofungicides in its 'Axpera' range, submitted in July 2024.

The pre-evaluation of the application for federal marketing authorization (AMM) has begun, the company points out, which means that a decision on marketing authorization is now expected within a theoretical period of seven months.

As a precautionary measure, Amoéba says it anticipates the EPA's conclusions in mid-2025, which means it is already working with provider Dunham Trimmer to launch its offer and select its future commercial partners.

If the approval deadlines are met, marketing authorization would enable the first distribution contracts to be recorded at the end of 2025.

In Europe, the EFSA review is now complete, and the European Food Safety Authority's final report should be published by December 2024 at the latest, Amoéba adds.

Following these announcements, the shares of the specialist in natural microbiological solutions based on amoebae climbed by over 7% on Thursday on the Paris stock exchange. Its gains since January 1 have reached almost 60%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.